在SLCO1B1中使用误解变异的基因风险评分与早期发病的他类药物不耐受性有关
Margherita Bigossi1,2, Cyrielle Maroteau3, Adem Y Dawed1
1Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Population Health & Genomics, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, DundeeDD1 9SY, UK.
使用常见的SLCO1B1变异的新基因风险评分 (GRS) 有效预测他类药物不耐受性,优于目前的遗传检测方法. 该工具有助于识别患有他类药物副作用风险的患者,改善治疗结果.
科学领域:
- 药物基因组学 药物基因组学
- 临床遗传学 临床遗传学
- 药物新陈代谢 药物新陈代谢
背景情况:
- 类固醇药物治疗的有效性受到患者不耐受性的限制,往往导致治疗中止.
- 在SLCO1B1中编码OATP1B1载体的遗传变异会影响他的药理动力学和血度.
- 目前的药物遗传学指南依赖于SLCO1B1基因测序,这比基因定型更昂贵,更难获得.
结论:
- 基于四种常见的SLCO1B1变体的GRS为估计他类药物不耐受风险提供了临床可执行的工具.
- 这种GRS比目前的推实践更可靠,用于预测早期出现的他类药物不耐受性.
- 这些发现支持使用这种GRS来个性化他类药物治疗和减轻不良事件.
更多相关视频
09:37Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Single Nucleotide Polymorphisms-SNPs
Relative Risk
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
